What Elicio Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 5 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 144,162 |
| Disposed | 0 | 0 |
| Net activity | +0 | +144,162 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Haqq Christopher | See Remarks | Feb 02 | Grant / award · A | +25,400 | — | — | 57,381 |
| DeMuth Peter | Chief Scientific Officer | Feb 02 | Grant / award · A | +20,800 | — | — | 21,543 |
| Connelly Robert | CEO, President and Director | Feb 02 | Grant / award · A | +73,600 | — | — | 120,570 |
| Shah Preetam | See Remarks | Feb 02 | Grant / award · A | +24,000 | — | — | 24,000 |
| DeMuth Peter | Chief Scientific Officer | Dec 09 | Exercise / conversion · M | +362 | $4.41 | +$1.6K | 743 |
| Chudnovsky Yekaterina | Director | Mar 05 | Derivative Conversion · C | +3,500,573 | $5.81 | +$20.3M | 5,416,212 |
| DeMuth Peter | Chief Scientific Officer | Dec 16 | Exercise / conversion · M | +381 | $4.41 | +$1.68K | 381 |
| Venkatesan Jay | Director | Nov 26 | In/At-money Exercise · X | +50,000 | $0.01 | +$500 | 179,581 |
| Chudnovsky Yekaterina | Director | Dec 22 | Open-market buy · P | +1,213,000 | $5.81 | +$7.05M | 1,915,639 |
| Goldberg Itzhak | Director | Jul 01 | Withheld — tax / exercise cost · F | −32,082 | $1.12 | −$35.9K | 1,687,986 |
| Venkatesan Jay | See Remarks | May 25 | Open-market buy · P | +11,313 | $1.25 | +$14.1K | 1,891,947 |
| Venkatesan Jay | See Remarks | May 24 | Open-market buy · P | +32,200 | $1.24 | +$39.9K | 1,721,457 |
| Nissenson Allen | Director | May 20 | Open-market buy · P | +2,037 | $1.18 | +$2.4K | 9,383 |
| Venkatesan Jay | See Remarks | May 20 | Open-market buy · P | +50,000 | $1.23 | +$61.5K | 1,689,257 |
| Nissenson Allen | Director | May 19 | Open-market buy · P | +7,346 | $1.16 | +$8.52K | 7,346 |
| Venkatesan Jay | See Remarks | Dec 28 | Open-market buy · P | +210,337 | $2.66 | +$560K | 1,639,257 |
| Venkatesan Jay | See Remarks | Dec 27 | Open-market buy · P | +66,907 | $2.55 | +$171K | 1,428,920 |
| Venkatesan Jay | See Remarks | Dec 20 | Open-market buy · P | +3,527 | $2.54 | +$8.98K | 1,362,013 |
| Neylan John F. | See Remarks | Dec 20 | Open-market sale · S | −358 | $2.62 | −$938 | 35,136 |
| Venkatesan Jay | See Remarks | Dec 17 | Open-market buy · P | +13,742 | $2.54 | +$35K | 1,358,486 |
Loading...